What happens when insurers stop covering expensive weight-loss drugs? In Massachusetts, use of GLP-1 medications for weight loss dropped 52% between 2025 and the first quarter of 2026, showing how quickly access can change when health plans pull back.
That shift translated to 112,000 fewer commercially insured people using the drugs for weight loss.
Here's what to know
New data from the Massachusetts Health Policy Commission, reported by Worcester Business Journal, showed that about three-quarters of GLP-1 spending in the state during 2025 was linked to weight loss. Before rebates and discounts, spending topped $2.3 billion, and net spending for commercially insured residents was nearly $1 billion.
That drop came after a period from 2019 to 2025 in which spending on GLP-1s for weight loss rose by an average of 99.5% per year. With weight-loss use down 52%, the commission said annualized 2026 spending fell to $662 million.
Insurer results varied, but several plans posted steep declines. Blue Cross Blue Shield of Massachusetts — which made up the largest share of the commission's sample — went from 6.1% of members using the drugs for weight loss in the fourth quarter of 2025 to 3.7% in the first quarter of 2026. Point32 fell from 6.5% to 3.3%, while Health New England dropped from 2.9% to 0.9%.
Several commercial and state plans stopped covering GLP-1s for weight loss in 2026, including the Group Insurance Commission, MassHealth, Blue Cross Blue Shield of Massachusetts, Point32Health, and Mass General Brigham Health Plan. Patients and clinicians said losing that benefit left patients' health "on the line."
TCD Picks » Quince Spotlight
💡These best-sellers from Quince deliver affordable, sustainable luxury for all
In 2025, patient cost-sharing totaled $136.3 million for weight-loss GLP-1s and $45.9 million for diabetes GLP-1s. Average monthly cost-sharing was $78 for weight loss and $66 for diabetes, levels the commission said had "generally remained stable." Coverage remained in place for people using GLP-1s for diabetes, but many seeking them for weight loss faced a new barrier.
What's being done?
As new GLP-1 drugs entered the market, net prices declined from 2019 through the first quarter of 2026, according to the Health Policy Commission. The agency expects 12 new GLP-1s by 2030, even though "blockbuster GLP-1s" remain patent-protected until 2041.
It also said Massachusetts commercial spending "would decrease significantly" if insurers paid prices closer to those negotiated by the Centers for Medicare and Medicaid Services or to international reference prices. Repricing Ozempic, Wegovy, Mounjaro, and Zepbound at Centers for Medicare and Medicaid Services-negotiated levels would reduce the commercial market by 32%, or $680 million; using international reference prices would cut it by 56% to 61%.
Looking ahead, Health and Human Services Secretary Kiame Mahaniah said he'd "be really surprised if within two years, we don't see a major price crash in terms of how much GLP-1s cost" and predicted that within two to three years, "we'll be back to full coverage."
Where can I learn more?
These stories offer more context on GLP-1 drugs, insurance pressures, and other approaches to weight and metabolic health, including the medications' wider effects, strains on the healthcare system, and diet and lifestyle factors tied to diabetes and weight loss.
• Scientists found potential emission savings from GLP-1-driven weight loss that were striking.
• A vegan diet can promote weight loss while shifting the conversation beyond prescription-based treatment.
• Researchers warned that vaping may raise diabetes risk alongside its better-known lung harms.
• A low-calorie Mediterranean diet may lower type 2 diabetes risk by 31%.
Get TCD's free newsletters for easy tips, smart advice, and a chance to earn $5,000 toward home upgrades. To see more stories like this one, change your Google preferences here.
